Naringin : antitumor potential in silico and in vitro on bladder cancer cells.
No Thumbnail Available
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Introduction: Urothelial carcinoma is a significant public health problem. Transitional cell carcinoma (TCC) is the
most common subtype, accounting for approximately 90 % of all bladder cancers. Chemotherapeutic protocols
have been studied, but some present high toxicity and low tolerability. Naringin is a polyphenolic compound found
mainly in citrus fruits, which antitumor activity has been studied in several types of cancer. However, there is little
information about naringin effects on bladder cancer. This study aimed to evaluate the antitumor potential of nar-
ingin in silico and in vitro using two bladder cancer cell lines
Method: In silico analysis was carried out by PASS Online software. In vitro, the effects of naringin treatment (12.5
- 400 μM) were evaluated regarding its cytotoxicity, clonogenic survival, morphological alterations, cell cycle pro-
gression, migration, and mutagenicity
Results: In silico analyses predicted antitumor activity through several mechanisms of action. In vitro results
showed naringin presented cytotoxic effects, reduced the number of colonies, inhibited cell migration, and changed
the morphology and cell cycle progression of the two cell lines evaluated. However, naringin did not present mu-
tagenic effects.
Conclusions: Naringin has antiproliferative activity and is a promising candidate for bladder cancer treatment.
Description
Keywords
Cell cycle progression, Flavonoid, Progresión del ciclo celular
Citation
RADICCHI, D. C. et al. Naringin: antitumor potential in silico and in vitro on bladder cancer cells. Ars Pharmaceutica, v. 63, p. 132-143, 2022. Disponível em: <https://revistaseug.ugr.es/index.php/ars/article/view/22430>. Acesso em: 11 out. 2022.